Structural characterization of human cytochrome P450 2C19: Active site differences between P450s 2C8, 2C9, and 2C19

Journal of Biological Chemistry

Volumn 287, Issue 53, 2012, Pages 44581-44591

  Reynald, R Leila ^a   Sansen, Stefaan ^a   Stout, C David ^a   Johnson, Eric F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; AMINO ACID RESIDUES; CHEMICAL COMPONENT; COMPUTATIONAL APPROACH; CONFORMATIONAL DIFFERENCES; CYTOCHROME P450; FLURBIPROFEN; HUMAN CYTOCHROME; HUMAN ENZYMES; METHANONE; PEPTIDE BACKBONES; PROTEIN DATA BANK; STRUCTURAL CHARACTERIZATION; STRUCTURAL ELEMENTS; STRUCTURAL FEATURE; SUBSTRATE-BINDING;

AMINO ACIDS; CONFORMATIONS; DATABASE SYSTEMS; PROTEINS; SUBSTRATES; X RAY CRYSTALLOGRAPHY;

ENZYMES;

AMINO ACID; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; FLURBIPROFEN;

ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ARYL HYDROCARBON HYDROXYLASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84871813154     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.424895     Document Type: Article

References (45)

1. Zanger, U. M., Turpeinen, M., Klein, K., and Schwab, M. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392, 1093-1108
2. Ingelman-Sundberg, M., and Sim, S. C. (2010) Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 396, 90-94
3. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., and Ghanayem, B. I. (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (Pubitemid 24089701)
4. Ingelman-Sundberg, M., Sim, S. C., Gomez, A., and Rodriguez-Antona, C. (2007) Influence of cytochrome P450 polymorphisms on drug therapies. Pharmacogenetic, pharmacoepigenetic, and clinical aspects. Pharmacol. Ther. 116, 496-526 (Pubitemid 350116943)
5. Spina, E., Santoro, V., and D'Arrigo, C. (2008) Clinically relevant pharmacokinetic drug interactions with second generation antidepressants. An update. Clin. Ther. 30, 1206-1227
6. Shi, S., and Klotz, U. (2008) Proton pump inhibitors. An update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 64, 935-951
7. Boulenc, X., Djebli, N., Shi, J., Perrin, L., Brian, W., Van Horn, R., and Hurbin, F. (2012) Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metab. Dispos. 40, 187-197
8. Zvyaga, T., Chang, S. Y., Chen, C., Yang, Z., Vuppugalla, R., Hurley, J., Thorndike, D., Wagner, A., Chimalakonda, A., and Rodrigues, A. D. (2012) Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450. Focus on cytochrome P450 2C19. Drug Metab. Dispos. 40, 1698-1711
9. Nishiya, Y., Hagihara, K., Kurihara, A., Okudaira, N., Farid, N. A., Okazaki, O., and Ikeda, T. (2009) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39, 836-843
10. Dansette, P. M., Libraire, J., Bertho, G., and Mansuy, D. (2009) Metabolic oxidative cleavage of thioesters. Evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem. Res. Toxicol. 22, 369-373
11. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T., and Kurihara, A. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92-99
12. Dansette, P. M., Rosi, J., Bertho, G., and Mansuy, D. (2012) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem. Res. Toxicol. 25, 348-356
13. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., Becquemont, L., and French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375
14. Cuisset, T., Morange, P. E., and Alessi, M. C. (2012) Recent advances in the pharmacogenetics of clopidogrel. Hum. Genet. 5, 693-664
15. Tiroch, K. A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schömig, A., and Kastrati, A. (2010) Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160, 506-512
16. Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., and Kastrati, A. (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518
17. Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid-binding site. J. Biol. Chem. 279, 9497-9503 (Pubitemid 38296017)
18. Schoch, G. A., Yano, J. K., Sansen, S., Dansette, P. M., Stout, C. D., and Johnson, E. F. (2008) Determinants of cytochrome P450 2C8 substrate binding. Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J. Biol. Chem. 283, 17227-17237
19. Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinkoviæ, D., and Jhoti, H. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464-468 (Pubitemid 36917499)
20. Wester, M. R., Yano, J. K., Schoch, G. A., Yang, C., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human microsomal cytochrome P450 2C9 complexed with flurbiprofen at 2.0 Å resolution. J. Biol. Chem. 279, 35630-35637 (Pubitemid 39100565)
21. Ibeanu, G. C., Ghanayem, B. I., Linko, P., Li, L., Pederson, L. G., and Goldstein, J. A. (1996) Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J. Biol. Chem. 271, 12496-12501 (Pubitemid 26160921)
22. Jung, F., Griffin, K. J., Song, W., Richardson, T. H., Yang, M., and Johnson, E. F. (1998) Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37, 16270-16279 (Pubitemid 28536263)
23. Klose, T. S., Ibeanu, G. C., Ghanayem, B. I., Pedersen, L. G., Li, L., Hall, S. D., and Goldstein, J. A. (1998) Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch. Biochem. Biophys. 357, 240-248 (Pubitemid 28419205)
24. Tsao, C. C., Wester, M. R., Ghanayem, B., Coulter, S. J., Chanas, B., Johnson, E. F., and Goldstein, J. A. (2001) Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 40, 1937-1944 (Pubitemid 32165662)
25. Wada, Y., Mitsuda, M., Ishihara, Y., Watanabe, M., Iwasaki, M., and Asahi, S. (2008) Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. J. Biochem. 144, 323-333
26. Locuson, C. W., 2nd, Suzuki, H., Rettie, A. E., and Jones, J. P. (2004) Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J. Med. Chem. 47, 6768-6776 (Pubitemid 40053765)
27. Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy, J. L., Kemper, B., Bornheim, L. M., Hassett, C., Omiecinski, C. J., and Johnson, E. F. (1995) Universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys. 323, 87-96
28. Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S., Chanas, B., Xi, T., Ghanayem, B., and Goldstein, J. A. (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703-711 (Pubitemid 36054937)
29. Wang, H., An, N., Wang, H., Gao, Y., Liu, D., Bian, T., Zhu, J., and Chen, C. (2011) Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4′-hydroxylation and omeprazole 5′-hydroxylation. Drug Metab. Dispos. 39, 830-837
30. Cosme, J., and Johnson, E. F. (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J. Biol. Chem. 275, 2545-2553 (Pubitemid 30082019)
31. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348-14355 (Pubitemid 47100434)
32. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem. 239, 2379-2385
33. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr.D Biol. Crystallogr. 62, 72-82
34. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464 (Pubitemid 43934606)
35. Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (Pubitemid 41742764)
36. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography and NMR system. A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921
37. Kleywegt, G. J., and Jones, T. A. (1994) Detection, delineation, measurement, and display of cavities in macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 50, 178-185 (Pubitemid 2054290)
38. Wang, A., Savas, U., Hsu, M. H., Stout, C. D., and Johnson, E. F. (2012) Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J. Biol. Chem. 287, 10834-10843
39. Mosher, C. M., Tai, G., and Rettie, A. E. (2009) CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. J. Pharmacol. Exp. Ther. 329, 938-944
40. Locuson, C. W., 2nd, Wahlstrom, J. L., Rock, D. A., Rock, D. A., and Jones, J. P. (2003)Anew class of CYP2C9 inhibitors. Probing 2C9 specificity with high affinity benzbromarone derivatives. Drug Metab. Dispos. 31, 967-971 (Pubitemid 36759068)
41. Ridderström, M., Masimirembwa, C., Trump-Kallmeyer, S., Ahlefelt, M., Otter, C., and Andersson, T. B. (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem. Biophys. Res. Commun. 270, 983-987 (Pubitemid 30444818)
42. Dickmann, L. J., Locuson, C. W., Jones, J. P., and Rettie, A. E. (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol. Pharmacol. 65, 842-850 (Pubitemid 38420489)
43. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dansette, P. M., Mansuy, D., and Stout, C. D. (2003) The structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution. Evidence for multiple substrate binding modes. Biochemistry 42, 6370-6379 (Pubitemid 36665811)
44. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dijols, S., Dansette, P. M., Mansuy, D., and Stout, C. D. (2003) The structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution. Evidence for an induced fit model of substrate binding. Biochemistry 42, 9335-9345 (Pubitemid 36959241)
45. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallgr. 66, (Pt. 1) 12-21